SE8401942D0 - Anti-tumour substance and process for producing the same - Google Patents

Anti-tumour substance and process for producing the same

Info

Publication number
SE8401942D0
SE8401942D0 SE8401942A SE8401942A SE8401942D0 SE 8401942 D0 SE8401942 D0 SE 8401942D0 SE 8401942 A SE8401942 A SE 8401942A SE 8401942 A SE8401942 A SE 8401942A SE 8401942 D0 SE8401942 D0 SE 8401942D0
Authority
SE
Sweden
Prior art keywords
producing
same
tumor
tumor substance
human immunoglobulin
Prior art date
Application number
SE8401942A
Other languages
English (en)
Other versions
SE462261B (sv
SE8401942L (sv
Inventor
Y Oguchi
K Niimura
T Fujii
M Fujii
K Matsunaga
C Yoshikumi
Original Assignee
Kureha Chemical Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Chemical Ind Co Ltd filed Critical Kureha Chemical Ind Co Ltd
Publication of SE8401942D0 publication Critical patent/SE8401942D0/sv
Publication of SE8401942L publication Critical patent/SE8401942L/sv
Publication of SE462261B publication Critical patent/SE462261B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
SE8401942A 1983-04-08 1984-04-06 Farmaceutisk komposition och konjugat av melfalan och normalt humanimmunoglobulin med antitumoerverkan samt foerfarande foer dess framstaellning SE462261B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58061923A JPS59186924A (ja) 1983-04-08 1983-04-08 ヒト免疫グロブリン結合抗腫瘍剤

Publications (3)

Publication Number Publication Date
SE8401942D0 true SE8401942D0 (sv) 1984-04-06
SE8401942L SE8401942L (sv) 1984-11-13
SE462261B SE462261B (sv) 1990-05-28

Family

ID=13185161

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8401942A SE462261B (sv) 1983-04-08 1984-04-06 Farmaceutisk komposition och konjugat av melfalan och normalt humanimmunoglobulin med antitumoerverkan samt foerfarande foer dess framstaellning
SE8904004A SE8904004L (sv) 1983-04-08 1989-11-27 Anti-tumoersubstans och foerfarande foer framstaellning av densamma

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8904004A SE8904004L (sv) 1983-04-08 1989-11-27 Anti-tumoersubstans och foerfarande foer framstaellning av densamma

Country Status (7)

Country Link
US (2) US4738843A (sv)
EP (1) EP0122132A3 (sv)
JP (1) JPS59186924A (sv)
CA (1) CA1301066C (sv)
DK (1) DK181484A (sv)
SE (2) SE462261B (sv)
ZA (1) ZA842272B (sv)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653682B2 (ja) * 1983-04-08 1994-07-20 呉羽化学工業株式会社 ヒト免疫グロブリン結合抗腫瘍剤
CA1260828A (en) * 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
FR2581313A1 (fr) * 1985-05-02 1986-11-07 Pasteur Institut Composes suscitant la formation d'anticorps, compositions immunogeniques et compositions immunoprotectrices les contenant et procede d'obtention d'anticorps les mettant en oeuvre
EP0250486A4 (en) * 1986-01-03 1988-05-25 Univ Melbourne MELPHALAN DERIVATIVES.
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
JPH0662438B1 (sv) * 1986-08-28 1994-08-17 Teijin Ltd
WO1988001513A1 (en) * 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
MY103231A (en) * 1987-03-11 1993-05-29 Univ Melbourne Immunoglobulin conjugates
US4900547A (en) * 1987-10-23 1990-02-13 University Of British Columbia Method to immunize mammals against tumors
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US4994440A (en) * 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
US6326467B1 (en) * 1989-02-23 2001-12-04 Colorado State University Research Foundation Hormone-recombinant toxin compounds and methods for using same
CA2021942C (en) * 1989-08-10 2001-04-10 Michel Page Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
ATE127018T1 (de) * 1992-03-06 1995-09-15 Fiutowski Zdzislaw Pharmazeutische zusammensetzung mit antiviraler und antibakterieller wirkung.
JP2578044B2 (ja) * 1992-03-14 1997-02-05 呉羽化学工業株式会社 フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
EP0679083A4 (en) * 1992-12-21 1999-03-24 Ophidian Pharm Inc PREVENTION AND TREATMENT OF SEPTICEMIA.
EP0608546A3 (en) * 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
PT923941E (pt) * 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
AU2006292433B2 (en) * 2005-09-20 2011-05-19 Amgen Inc. Method for generating F(ab')2 antibody fragments
ES2473665T3 (es) 2005-11-28 2014-07-07 Verrow Pharmaceuticals, Inc. Composiciones útiles para reducir la nefrotoxicidad y los métodos de uso de las mismas
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN104800856A (zh) * 2007-04-10 2015-07-29 日东电工株式会社 多功能聚谷氨酸盐药物载体
JP2010526917A (ja) * 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
EP2155255B1 (en) 2007-05-09 2013-08-14 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
WO2008141111A2 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Polymers conjugated with platinum drugs
EP2265274B1 (en) 2008-03-03 2018-11-21 Tosk, Inc. Methotrexate adjuvants to reduce toxicity and methods for using the same
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US10723160B2 (en) 2018-01-23 2020-07-28 Ferro Corporation Carbide, nitride and silicide enhancers for laser absorption
US10854554B2 (en) 2018-01-23 2020-12-01 Ferro Corporation Carbide, nitride and silicide enhancers for laser absorption

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509707A (en) * 1974-09-20 1978-05-04 Searle & Co Immunological compounds
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
US4017471A (en) * 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
JPS5364617A (en) * 1976-11-22 1978-06-09 Furukawa Electric Co Ltd:The Manufacture of oxygen-free high-conductivity copper
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4493793A (en) * 1978-12-26 1985-01-15 E-Y Laboratories Soluble immunoassay reagent comprising lectin covalently bonded to reactive component
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法

Also Published As

Publication number Publication date
EP0122132A3 (en) 1985-11-27
SE8904004D0 (sv) 1989-11-27
JPS6330289B2 (sv) 1988-06-17
US4738843A (en) 1988-04-19
ZA842272B (en) 1984-11-28
SE462261B (sv) 1990-05-28
DK181484A (da) 1984-10-09
EP0122132A2 (en) 1984-10-17
JPS59186924A (ja) 1984-10-23
CA1301066C (en) 1992-05-19
SE8401942L (sv) 1984-11-13
DK181484D0 (da) 1984-04-06
US4925662A (en) 1990-05-15
SE8904004L (sv) 1991-05-28

Similar Documents

Publication Publication Date Title
SE8401942D0 (sv) Anti-tumour substance and process for producing the same
DE3485466D1 (de) Schichtkoerper und verfahren zur herstellung desselben.
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
NO845117L (no) Framgangsmaate for smiing av superlegeringer.
NO861445L (no) Naske-sikker kapsel, og fremgangsmaate og anordning for fremstilling av samme.
DE3575241D1 (de) Halbleiteranordnung und verfahren zum herstellen derselben.
NO160362C (no) Fremgangsmaate for fremstilling av tert.- butylaminoetoksyetanol.
IT8422234A0 (it) Procedimento per la preparazione di penem.
FR2521982B1 (fr) Composite alumine-alumine et son procede de fabrication
DE3772490D1 (de) Halbleiteranordnung sowie verfahren zum herstellen und testen derselben.
NO830570L (no) Antistoffer og antigener for diagnose og behandling av cancer
BR8401538A (pt) Conjunto de selo para laminador
DE3378216D1 (en) Ethylene-propylene block-copolymers and process for producing the same
GB2143989B (en) Radiation source
IT8420726A0 (it) Procedimento per produrre dispositivi semiconduttori.
NO854453L (no) Fremgangsmaate og anordning for fremstilling av laminater.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
NO871242D0 (no) Transportoerbelte og fremgangsmaate for fremstilling av samme.
BR8400420A (pt) Cabina de tratamento
HUT36783A (en) Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane
DE3375830D1 (en) Humidity-sensitive element and process for producing the same
DK529084A (da) Aryl-substituerede imidazo-forbindelser og fremgangsmaade til fremstilling heraf
NO901512L (no) Framgangsmaate for framstilling/renovering av vinduer.
EP0315134A3 (en) Synchrotron radiation source and method of making the same
EP0116304A3 (en) Composite optical semiconductor device

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8401942-1

Effective date: 19921108

Format of ref document f/p: F